Issue 27, 2020

Nanomaterial synthesis, an enabler of amyloidosis inhibition against human diseases

Abstract

Amyloid diseases are global epidemics with no cure currently available. In the past decade, the use of engineered nanomaterials as inhibitors or probes against the pathogenic aggregation of amyloid peptides and proteins has emerged as a new frontier in nanomedicine. In this Minireview, we summarize for the first time the pivotal role of chemical synthesis in enabling the development of this multidisciplinary field.

Graphical abstract: Nanomaterial synthesis, an enabler of amyloidosis inhibition against human diseases

Article information

Article type
Minireview
Submitted
04 jun 2020
Accepted
30 jun 2020
First published
30 jun 2020

Nanoscale, 2020,12, 14422-14440

Nanomaterial synthesis, an enabler of amyloidosis inhibition against human diseases

N. Andrikopoulos, Y. Li, L. Cecchetto, A. Nandakumar, T. Da Ros, T. P. Davis, K. Velonia and P. C. Ke, Nanoscale, 2020, 12, 14422 DOI: 10.1039/D0NR04273K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements